Market Overview

My goal is to be on stage with my computer and let you
see my screen and make sure you know what buttons to
press, where you’re getting in & out, how to calculate
risk, your targets — all of those things.
It’s real-life trading. Make sure you sign up!
- Jerremy Newsome
GET TICKETS

Benzinga's Top Upgrades

Share:
Benzinga's Top Upgrades

Analysts at Wunderlich upgraded NetScout Systems (NASDAQ: NTCT) from “hold” to “buy.” The target price for NetScout Systems has been raised from $35 to $46. NetScout's shares closed at $38.70 yesterday.

Bank of America upgraded Selective Insurance Group (NASDAQ: SIGI) from “neutral” to “buy.” The target price for Selective Insurance is set to $26. Selective Insurance's shares closed at $22.64 yesterday.

Analysts at Piper Jaffray upgraded DeVry Education Group (NYSE: DV) from “neutral” to “overweight.” The target price for DeVry has been raised from $34 to $54. DeVry's shares closed at $40.36 yesterday.

Stifel Nicolaus upgraded Under Armour (NYSE: UA) from “hold” to “buy.” The target price for Under Armour is set to $65. Under Armour's shares closed at $50.42 yesterday.

Latest Ratings for NTCT

DateFirmActionFromTo
Apr 2019DowngradesOverweightNeutral
May 2018TerminatesNeutralNeutral
Jan 2018MaintainsBuy

View More Analyst Ratings for NTCT
View the Latest Analyst Ratings

Posted-In: top upgradesUpgrades Analyst Ratings

 

Related Articles (NTCT + DV)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
IQVMaintains150.0
MSFTMaintains155.0
MDBMaintains185.0
ADBEMaintains320.0
MRTXDowngrades92.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Benzinga's Top Initiations

UPDATE: Cytokinetics Reports Top-Line Results from BENEFIT-ALS Showed Did Not Reach Primary Efficacy Endpoint, Mixed Effects on Secondary Endpoints